HMGB1 and Cognitive impairment: A clinical study validating the non-invasive clinical biomarkers of BBB dysfunction and neuroinflammation to evaluate the progression towards neurodegeneration in mild cognitive impairment (MCI) and AD patients detected upregulated expression and/or release of serum HMGB1 and sRAGE, correlated with Aβ levels in AD patients [92].